<head>
    <!-- Stylesheet -->
    <link rel="stylesheet" href="css/pctl.css">
</head>

<!-- Main -->
<main>
    <h2 class="primary">PTCL Is a Rare, Aggressive Lymphoma That Often Requires Multiple Lines of Therapy to Attempt to Delay Disease Progression<sup>3-5</sup></h2>
    <h3 class="secondary-variant">In the COMPLETE registry (N = 499), a >50% CR was observed in newly diagnosed patients with the most common subtypes of PTCL following induction therapy<sup>4,*</sup>
    </h3>
    <div class="response-rate">
        <h4>Observed response rates<sup>†</sup> following induction therapy for patients with PTCL-NOS, AITL, and ALK-negative ALCL (n = 227)<sup>5</sup>
        </h4>
        <div class="response-rate-data">
            <span class="stacked-superscript secondary-variant">57<sup>%</sup><span>CR</span></span>
            <span class="line"></span>
            <span class="stacked-superscript secondary">13<sup>%</sup><span>PR</span></span>
        </div>
    </div>
    <h3 class="secondary-variant">Yet among 97 primary refractory patients (PR, PD, or SD) and 58 relapsed patients available for evaluation, the majority experienced R/R disease within 1 year after initial diagnosis<sup>5</sup>
    </h3>
    <h4 class="center">Observed median time from PTCL diagnosis to R/R PTCL<sup>5</sup>
    </h4>
    <div class="median">
        <div class="median__figure">
            <h4 class="primary">First relapse (n = 58)<sup>‡</sup></h4>
            <h1>12.1 months</h1>
            <h4 class="primary">(range, 8.5-20.5 months)
            </h4>
        </div>
        <hr width="1" size="150">
        <div class="median__figure">
            <h4 class="primary">Primary refractory (n = 97)<sup>§</sup></h4>
            <h1>3.8 months</h1>
            <h4 class="primary">(range, 2.4-6.0 months)</h4>
        </div>
    </div>
    <h4 class="secondary-variant semibold">In the T-Cell Project registry (N = 937), 68% were identified as R/R. The median time to relapse was 8 months (range, 2-73 months)<sup>6</sup>
    </h4>
    <p class="light"><sup>*</sup>Initial treatment strategy was determined by treating physicians. <sup>†</sup>Response assessment was undertaken by the treating investigator according to the Revised Response Criteria for Malignant Lymphoma. <sup>§</sup>PTCL-NOS (29%), AITL (14%), ALK-negative ALCL (14%), and other (48%). <sup>‡</sup>PTCL-NOS (26%), AITL (22%), ALK-negative ALCL (9%), and other (31%).</p>
    <p class="light">AITL, angioimmunoblastic T-cell lymphoma; ALK, anaplastic lymphoma kinase; ALCL, anaplastic large cell lymphoma; CR, complete response; PD, progressive disease; PTCL, peripheral T-cell lymphoma; PTCL-NOS, PTCL not otherwise specified; R/R, relapsed/refractory; SD, stable disease.</p>
    <div class="button-group">
        <a href="" ui-sref="PTCL2" class="button justify-right">Next <i class="fas fa-chevron-right"></i></a>
    </div>
</main>
